

**SCIENTIFIC ADVISORY COMMITTEE ON ALTERNATIVE TOXICOLOGICAL METHODS**  
**DECEMBER 5, 2002**  
**CRYSTAL GATEWAY MARRIOTT, ARLINGTON, VIRGINIA**

**DECEMBER 5, 2002**

9:00 AM	<b>CALL TO ORDER, INTRODUCTIONS</b>	Dr. Jack Dean, Sanofi-Synthelabo, Inc., Chair Dr. Christopher Portier, NIH/NIEHS Dr. Leonard Schechtman, FDA/NCTR
9:15 AM	<b>INFORMATIONAL OVERVIEWS</b> <ul style="list-style-type: none"><li>• National Institute of Environmental Health Sciences (NIEHS) and National Toxicology Program (NTP) (20')</li><li>• NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (20')</li><li>• Committee Questions and Answers</li></ul>	Dr. Portier Dr. William Stokes, NIH/NIEHS
10:05 AM	<b>ICCVAM VALIDATION AND ACCEPTANCE CRITERIA (20')</b> <ul style="list-style-type: none"><li>• Committee Questions and Answers</li></ul>	Dr. Stokes
10:45 AM	<b>BREAK</b>	
11:05 AM	<b>WELCOMING REMARKS</b>	Dr. Kenneth Olden, NIH/NIEHS
11:15 AM	<b>CURRENT SCIENTIFIC DIRECTIONS OF THE EUROPEAN CENTRE FOR THE VALIDATION OF ALTERNATIVE METHODS (ECVAM) (15')</b>	Dr. Thomas Hartung, ECVAM
	<b>LINKAGE OF SCIENTIFIC DIRECTIONS BETWEEN ECVAM AND ICCVAM (15')</b> <ul style="list-style-type: none"><li>• Public Comment</li><li>• Committee Discussion</li></ul>	Dr. Schechtman
12:15 PM	<b>LUNCH</b> (on your own)	

1:15 PM	<b>TEST METHOD SUBMISSIONS AND PROPOSED NOMINATIO AND PRIORITIZATION PROCESS (20')</b> <ul style="list-style-type: none"> <li>• Public Comments</li> <li>• Board Discussion</li> </ul>	Dr. Stokes
2:15 PM	<b><u>IN VITRO</u> ACUTE TOXICITY TESTING METHODS</b> <ul style="list-style-type: none"> <li>• Summary of Workshop Recommendations (15') Chair of</li> <li>• Current Activities (15')</li> <li>• Public Comment</li> <li>• Committee Discussion</li> </ul>	Dr. Katherine Stitzel, Co-  the Breakout Group <u>In Vitro</u> Methods for Organ Specific Toxicity Dr. Stokes
3:15 AM	<b><i>BREAK</i></b>	
3:35 PM	<b><u>IN VITRO</u> ESTROGEN/ANDROGEN RECEPTOR BINDING AND TRANSCRIPTIONAL ACTIVATION ASSAYS</b> <ul style="list-style-type: none"> <li>• Summary of Panel Recommendations (15')</li> <li>• Current Activities (15')</li> <li>• Public Comment</li> <li>• Committee Discussion</li> </ul>	Dr. George Datson, The Proctor and Gamble Company, Chair of the Endocrine Disruptor Expert Panel Meeting Dr. John Bucher, NIH/NIEHS
4:35 PM	<b>OTHER BUSINESS</b>	
5:00 PM	<b><i>ADJOURN</i></b>	